# Androgen Reduction in Congenital Adrenal Hyperplasia

> **NCT03548246** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Placebo
- **DRUG:** Hydrocortisone
- **DRUG:** Fludrocortisone

## Key facts

- **NCT ID:** NCT03548246
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study plan has halted and was withdrawn from the IRB.
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548246, "Androgen Reduction in Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03548246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*